Intercept's INT-747 meets Phase II endpoint

Intercept Pharmaceuticals Inc. (New York, N.Y.) said INT-747 met the primary endpoint of significantly improving insulin sensitization at six weeks vs. placebo in a Phase II trial to treat Type II dia...